Annexon Completes Enrollment in Phase 3 ARCHER II Trial of Vonaprument for GA

Annexon announced enrollment has been completed in the phase 3 ARCHER II trial of vonaprument (formerly ANX007) for dry age-related macular degeneration (AMD) with geographic atrophy (GA). The company remains on track to report topline data in the second half of 2026.

According to Annexon, vonaprument is a first-in-kind, non-pegylated antigen-binding fragment (Fab) designed to block C1q locally in the eye with an intravitreal formulation. The neuroprotective effect and consistent benefits of C1q inhibition were previously demonstrated by vonaprument in a phase 2 trial. Vonaprument is the only investigational therapy for dry AMD with GA to show significant vision preservation based upon best corrected visual acuity (BCVA) and low luminance visual acuity (LLVA).

ARCHER II is a global, randomized, double-masked, sham-controlled pivotal trial designed to assess both visual acuity and structural measures to satisfy the global registration path in the US and Europe. Vonaprument has received Priority Medicine (PRIME) designation in Europe and Fast Track designation in the US.

“Achieving and surpassing our enrollment goal ahead of schedule in ARCHER II highlights the strong interest for a treatment that can help patients preserve their vision,” Douglas Love, president and chief executive officer of Annexon, said in a company news release. “ARCHER II is designed to confirm the protection of visual acuity and visual structures demonstrated previously in our phase 2 trial, and we look forward to reporting topline pivotal data in the second half of 2026. The power of our classical complement platform continues to achieve differentiated functional benefits across indications, and we remain committed to our goal of making and shaping markets with first-in-kind medicines that will help millions of patients live their best lives.”

An oral presentation by David Eichenbaum, MD, Director of Research at the Retina Vitreous Associates of Florida on the design and rationale of the pivotal phase 3 ARCHER II trial will take place on Thursday, July 31, 2025, at the American Society of Retina Specialists (ASRS) annual meeting held in Long Beach, CA.

ASRS Annual Meeting Oral Presentation
Dry AMD Symposium 2 
“ARCHER II, a Phase 3 Randomized Clinical Trial of ANX007 in Patients With Dry AMD and GA: Study Design and Rationale Informed by Outcomes From ARCHER”

• Presenter: David A. Eichenbaum, MD, FASRS, Retina Specialist, Retina Vitreous Associates of Florida
• Date/Time: Thursday, July 31 at 2:59 pm Pacific Time (PT)